Further molecular studies and future clinical trials using NF-κB and STAT5 inhibitors will address clinical benefits of targeting Bcl-xL as an approach toward enhancing the efficacy of chemotherapy in ovarian cancer patients. This evidence concerns the gene STAT5B and ovarian carcinoma.